In-vitro effect of a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) on human gastric cancer cell lines: Timing of cisplatin treatment

被引：7

作者：

Cho H. ^{[1
]}

Imada T. ^{[1
]}

Oshima T. ^{[1
]}

Shiozawa M. ^{[1
]}

Rino Y. ^{[1
]}

Takanashi Y. ^{[1
]}

机构：

[1] First Department of Surgery, Yokohama City University, School of Medicine, Yokohama

来源：

Gastric Cancer | 2002年 / 5卷 / 1期

关键词：

5-Fluorouracil; Cisplatin; Gastric cancer;

D O I：

10.1007/s101200200006

中图分类号：

学科分类号：

摘要：

Background. To date, we have few effective chemotherapeutic agents against advanced and recurrent gastric cancer. 5-Fluorouracil (5-FU) and cisplatin (CDDP) are the most widely used drugs, and their combination has demonstrated favorable outcomes. However, the method (especially the timing) of CDDP administration is not well established. Methods. We examined the in-vitro effect of a combination of 5-FU and CDDP on four human gastric cancer cell lines: MKN-1, MKN-28, MKN-45, and MKN-74. The cell lines were exposed to 50% of the inhibitory concentrations of 5-FU and CDDP for 72h and 8h, respectively. CDDP was applied before, simultaneously with, and after the start of treatment with 5-FU. Results. When CDDP was applied after 5-FU, the cytotoxic activity against MKN-28, MKN-45, and MKN-74 was significantly potentiated. Against MKN-1, the earlier the initiation of CDDP treatment, the stronger was the cytotoxic effect. Conclusion. Our results suggest that the cytotoxicity of a combination of 5-FU and CDDP against human gastric cancer cells is both cell-line- and schedule-dependent and is especially affected by the timing of the CDDP treatment.

引用

页码：43 / 46

页数：3

共 14 条

[1]

Greenberg B., Ahmann F., Garewal H., Koopmann C., Coulthard S., Berzes H., Et al., Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluovouracil and cisplatin, Cancer, 59, pp. 1860-1865, (1987)

[2]

Kish J.A., Ensley J.F., Jacobs J.R., Binns P., Al-Sarraf M., Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer, Am J Clin Oncol, 11, pp. 553-557, (1988)

[3]

Rooney M., Kish J., Jacobs J., Kinzie J., Weaver A., Crissman J., Et al., Improved complete response rates and survival in advanced head and neck cancer after three-course induction therapy with 120 hours 5-FU infusion and cisplatin, Cancer, 55, pp. 1123-1128, (1985)

[4]

Kondo K., Murase M., Kodera Y., Akiyama S., Ito K., Yokoyama Y., Et al., Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer, Oncology, 53, pp. 64-67, (1996)

[5]

Ohtsu A., Shimada Y., Yoshida S., Saito H., Seki S., Morise K., Et al., Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG), Eur J Cancer, 30, pp. 2091-2093, (1994)

[6]

Rougier Ph., Ducreux M., Mahjoubi M., Pigmon J.P., Bellefqih S., Oliveira J., Et al., Efficacy of combined 5-fluorouracil and cisplatin in advanced gastric carcinomas. A phase II trial with prognostic factor analysis, Eur J Cancer, 30, pp. 1263-1269, (1994)

[7]

Scanlon K.J., Newman E.M., Lu Y., Priest D.G., Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells, Proc Natl Acad Sci USA, 83, pp. 8923-8925, (1986)

[8]

Shirasaka T., Shimamoto Y., Ohsimo H., Saito H., Fukushima M., Metabolic basis of the synergistic antitumor activities of 5-fluorouracil, Cancer Chemother Pharmacol, 32, pp. 167-172, (1993)

[9]

Esaki T., Nakano S., Tatsumoto T., Kuroki-Migita M., Mitsugi K., Nakamura M., Et al., Inhibition by 5-fluorouracil of cisdiamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line, Cancer Res, 52, pp. 6501-6506, (1992)

[10]

Alley M.C., Scudiero D.A., Monks A., Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay, Cancer Res, 48, pp. 589-601, (1988)

← 1 2 →